Concepedia

Apalutamide and Overall Survival in Prostate Cancer

Matthew R. Smith, Fred Saad, Simon Chowdhury, Stéphane Oudard, Boris Hadaschik, Julie N. Graff, David Olmos, Paul N. Mainwaring, Ji Youl Lee, Hiroji Uemura,

European Urology · 2020 · 277 citations · 20 references

DOIFull text

Open access

Abstract

With data presented herein, all primary and secondary study end points of SPARTAN were met; findings demonstrate the value of apalutamide as a treatment option for nonmetastatic castration-resistant prostate cancer.

References

20

Design and End Points of Clinical Trials for Patients With Progressive Prostate Cancer and Castrate Levels of Testosterone: Recommendations of the Prostate Cancer Clinical Trials Working Group

Howard I. Scher, Susan Halabi, Ian F. Tannock et al. · Journal of Clinical Oncology · 2008 · 2.2K citations · Full text

Apalutamide for Metastatic, Castration-Sensitive Prostate Cancer

Kim N., Neeraj Agarwal, Anders Bjartell et al. · New England Journal of Medicine · 2019 · 1.4K citations · Full text

Abiraterone acetate plus prednisone versus placebo plus prednisone in chemotherapy-naive men with metastatic castration-resistant prostate cancer (COU-AA-302): final overall survival analysis of a randomised, double-blind, placebo-controlled phase 3 study

Charles J. Ryan, Matthew R. Smith, Karim Fizazi et al. · The Lancet Oncology · 2015 · 1.3K citations

, , +7

Apalutamide Treatment and Metastasis-free Survival in Prostate Cancer

Matthew R. Smith, Fred Saad, Simon Chowdhury et al. · New England Journal of Medicine · 2018 · 1.3K citations · Full text

Enzalutamide in Men with Nonmetastatic, Castration-Resistant Prostate Cancer

Maha Hussain, Karim Fizazi, Fred Saad et al. · New England Journal of Medicine · 2018 · 1K citations · Full text